200 articles
Equity Research
Company-level stock analysis, valuation, margins, balance sheet risk, and rating rationale.
Research
134 articles
The Scorecard
Post-publication reviews that check what happened after earlier Buy and Sell calls.
97 articles
SEC What Changed
Daily filing-change notes comparing new 10-K language with prior-year disclosures.
11 articles
Weekly Performance
Friday performance updates for the public LF0 research track record.
Smith & Wesson (SWBI) 2026 10-K Analysis: MD&A Filing Changes
Smith & Wesson (SWBI) 2026 10-K analysis comparing MD&A changes, sales growth, tariff pressure, debt reduction, and capital allocation versus 2025.
Smith & Wesson Brands (SWBI) 2026 10-K Analysis: MD&A Changes
Smith & Wesson Brands (SWBI) 2026 10-K analysis comparing the 17 June 2026 filing with its prior-year 10-K, highlighting the MD&A section’s biggest changes.
SEC What Changed: 10-K Filing Snapshot for 16 June 2026
A ranked snapshot of 10-K language changes for companies that filed annual reports on 16 June 2026.
Vistagen Therapeutics (VTGN) 10-K Business Changes | 15 June 2026
Vistagen Therapeutics (VTGN)’s Business section changed the most among 7 companies that filed 10-Ks on 15 June 2026, each compared against its prior-year filing.
SEC What Changed: 10-K Filing Snapshot for 12 June 2026
A ranked snapshot of 10-K language changes for companies that filed annual reports on 12 June 2026.
SEC What Changed: 10-K Filing Snapshot for 11 June 2026
A ranked snapshot of 10-K language changes for companies that filed annual reports on 11 June 2026.
Waitlist
Join the lf0 premium research waitlist.
More detailed equity research, scorecards, and performance analysis are coming. Add your email to be first in line.